4 ms·
Celgene are currently engaged in shenanigans in the UK. There are currently two main chemotherapies used for pancreatic cancer in England. First line is folfi
by DanBC 11y ago
Celgene are currently engaged in shenanigans in the UK.
There are currently two main chemotherapies used for pancreatic cancer in England. First line is folfirinox. But that can have nasty side effects, so the less effective gemcitabine is used because it has less side effects.
Celgene make abraxane. Abraxane (by Celgene's own data) isn't as good as current first treatment; and has many side effects so can't be used as second line treatment.
Celgene's data shows median life extension on abraxane as two months.
A charity - pancreaticcanceraction.org - has started a petition to get NICE to change the decision. The petition states abraxane gives two years extra life which is true for a few people. Equally true would be "abraxane gives two days extra life".
The shenanigans come from the amount of funding and campaigning material Celgene has provided to pancreaticcanceraction.org, while making it seem like they don't have any connection.
https://www.nice.org.uk/news/press-and-media/the-cost-of-nab-paclitaxel-is-not-justified-by-its-limited-benefit-says-nice-in-draft-guidance-2 https://www.nice.org.uk/news/press-and-media/the-cost-of-nab...
https://pancreaticcanceraction.org/news/english-patients-nice-decides-fund-abraxane/ https://pancreaticcanceraction.org/news/english-patients-nic...